Safety and Efficacy Exploratory Study of the Use of Fasudil hydrochloride for Vasospasm on arteriovenous fistula construction - SAEF-AVF study

akamura Motonobu0 个研究点目标入组 10 人开始时间: 2023年3月14日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1. Patients with end-stage renal failure
•2. Those planning to construct an AVF using the radial artery-radial cutaneous vein
•3. Age: Persons who are over 18 and under 90 years of age at the time of obtaining consent
•4. Gender: any gender
•5. Those who have given written consent of their own free will after receiving a sufficient explanation for participating in this research.
•6. Those who can make outpatient visits in accordance with the research implementation schedule

•1. Those with low blood pressure (systolic blood pressure: 100 mmHg or less)
•2. Those with possible intracranial hemorrhage
•3. Those with hepatic dysfunction
•4. Those who received fasudil hydrochloride within 12 weeks prior to obtaining consent
•5. Those complicated with malignant tumors
•6. Those with a history of serious drug allergy such as anaphylactic shock or a history of serious adverse drug reactions
•7. Those who have participated in a clinical trial or clinical study and taken study medication within 4 weeks prior to obtaining consent
•8. Those who have attempted to construct an AVF in the past
•9. Those who are pregnant or possibly pregnant
•10. Those who are breastfeeding
•11. Those deemed by the principal investigator or sub investigator to be inappropriate to participate in this study

发起方

akamura Motonobu